Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.24 -5.1%	$3.58	$1.89 ▼ $5.82	$1.33B	0.64	6.46 million shs	6.64 million shs
ADPT Adaptive Biotechnologies	$10.33 +0.9%	$10.67	$3.85 ▼ $12.43	$1.56B	1.92	1.54 million shs	1.71 million shs
GOSS Gossamer Bio	$2.00 -2.0%	$1.41	$0.66 ▼ $2.18	$463.70M	1.95	2.78 million shs	2.69 million shs
JANX Janux Therapeutics	$23.56 -1.9%	$24.74	$22.48 ▼ $71.71	$1.42B	2.86	800,036 shs	601,583 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-5.15%	-17.03%	+13.07%	+75.93%	+30.06%
ADPT Adaptive Biotechnologies	+0.88%	-3.91%	-10.02%	+4.98%	+127.03%
GOSS Gossamer Bio	-1.96%	+8.70%	+65.29%	+69.49%	+121.41%
JANX Janux Therapeutics	-1.87%	-9.24%	-2.08%	-28.35%	-41.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4221 of 5 stars	3.5	1.0	0.0	3.1	3.3	0.0
ADPT Adaptive Biotechnologies	3.0058 of 5 stars	1.4	2.0	4.2	2.8	2.5	0.6
GOSS Gossamer Bio	3.9158 of 5 stars	3.5	1.0	4.7	3.8	1.7	0.0
JANX Janux Therapeutics	2.4078 of 5 stars	3.5	2.0	0.0	3.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.75	106.37% Upside
ADPT Adaptive Biotechnologies	2.83	Moderate Buy	$11.33	9.71% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	312.50% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	290.02% Upside

Current Analyst Ratings Breakdown

Latest GOSS, ADPT, JANX, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	43.89	N/A	N/A	$3.58 per share	1.18
ADPT Adaptive Biotechnologies	$178.96M	8.77	N/A	N/A	$1.37 per share	7.54
GOSS Gossamer Bio	$114.70M	3.96	N/A	N/A	$0.13 per share	15.38
JANX Janux Therapeutics	$9.34M	149.33	N/A	N/A	$19.49 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)

Latest GOSS, ADPT, JANX, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	$49.40 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
GOSS Gossamer Bio	6.70	5.71	5.71
JANX Janux Therapeutics	N/A	58.47	58.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ADPT Adaptive Biotechnologies	99.17%
GOSS Gossamer Bio	81.23%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
ADPT Adaptive Biotechnologies	6.40%
GOSS Gossamer Bio	6.70%
JANX Janux Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
JANX Janux Therapeutics	30	59.18 million	54.38 million	Optionable

GOSS, ADPT, JANX, and ABCL Headlines

Recent News About These Companies

Janux Therapeutics (JANX) Expected to Announce Quarterly Earnings on Wednesday

July 31 at 6:14 AM | marketbeat.com

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

July 31 at 2:11 AM | seekingalpha.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Bank of New York Mellon Corp

July 29, 2025 | marketbeat.com

Skandinaviska Enskilda Banken AB publ Sells 27,347 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 28, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

July 28, 2025 | marketbeat.com

Victory Capital Management Inc. Purchases 23,242 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 26, 2025 | marketbeat.com

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

July 24, 2025 | businesswire.com

Readystate Asset Management LP Cuts Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

July 22, 2025 | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 52,896 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 22, 2025 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.8% - Here's What Happened

July 19, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC

July 19, 2025 | marketbeat.com

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

July 17, 2025 | businesswire.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.5% - Still a Buy?

July 16, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Recommendation of "Buy" from Brokerages

July 16, 2025 | marketbeat.com

Raymond James Initiates Coverage of Janux Therapeutics (JANX) with Outperform Recommendation

July 12, 2025 | msn.com

Janux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Janux Therapeutics Inc Ordinary Shares JANX - Morningstar

June 27, 2025 | morningstar.comM

JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target

June 24, 2025 | msn.com

Janux Therapeutics Becomes Oversold (JANX)

June 20, 2025 | nasdaq.com

Why Janux Therapeutics, Inc.’s (JANX) Stock Is Down 7.22%

May 15, 2025 | aaii.comA

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 15, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, ADPT, JANX, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.24 -0.23 (-5.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.23 -0.01 (-0.21%)

As of 08/1/2025 08:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Adaptive Biotechnologies NASDAQ:ADPT

$10.33 +0.09 (+0.88%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.25 -0.08 (-0.77%)

As of 08/1/2025 07:16 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Gossamer Bio NASDAQ:GOSS

$2.00 -0.04 (-1.96%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/1/2025 07:07 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Janux Therapeutics NASDAQ:JANX

$23.56 -0.45 (-1.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$23.59 +0.03 (+0.13%)

As of 08/1/2025 06:04 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time